REGENERON PHARMACEUTICALS, INC. (REGN) Stock Analysis

Analysis from 10-Q filed 2025-10-28. Data as of Q3 2025.

Overall Grade: F (Concerning)

Grade F (Concerning). ROIC 14.1%. FCF margin 29.6%. D/E 0.1x. Source: 10-Q filed 2025-10-28.

Metric	Value	Context
ROIC	14.1%	Solid returns
FCF Margin	29.6%	Strong cash generation
Debt/Equity	0.1x	Conservative leverage

ROIC 14.1% — Top 25% of sector peers. FCF margin 29.6% — Top 5%.

Explore REGENERON PHARMACEUTICALS, INC.: Earnings History | Filings | ROIC Analysis

Programmatic access: Available via MCP at mcp.metricduck.com. Tools for REGN: get_company_overview, get_filing_index (lens: debt_stress, management_outlook, risk_trajectory), get_filing_changes, get_metric_history, compare_companies, screen_filing_signals.

---

Profitability: REGENERON PHARMACEUTICALS, INC. earns 14.1% ROIC, Top 25% in Healthcare

ROIC TTM 14.1%, sector median -2.6%, Top 25%. DuPont: NOPAT margin 23.0% × asset turnover 0.4x. Gross margin 100.0%. Operating margin 25.9%. Source: 10-Q filed 2025-10-28.

Metric	REGN	Rating	Context
Return on Invested Capital (ROIC)	14.1%	Good	Above sector median of -2.6%
Return on Equity (ROE)	15.4%	Good	Efficient use of shareholder equity
Gross Margin	100.0%	Excellent	Strong pricing power
Operating Margin	25.9%	Excellent	Efficient operations

---

Cash Flow: REGENERON PHARMACEUTICALS, INC. generates $4.2B FCF at 29.6% margin, positive NaN/8 quarters

FCF TTM $4.2B. FCF margin 29.6%, Top 5%. OCF/Net income 1.1x. Positive FCF in NaN/8 trailing quarters. Source: 10-Q filed 2025-10-28.

Metric	REGN	Rating	Context
Free Cash Flow Margin	29.6%	Excellent	Excellent cash conversion
Free Cash Flow (TTM)	$4.2B	Good	Positive cash generation
OCF/Net Income	1.1x	Excellent	High earnings quality
FCF Consistency (8Q)	N/A	Warning	Variable cash flow

---

Balance Sheet: REGENERON PHARMACEUTICALS, INC. at 0.1x leverage

Debt/Equity 0.1x. Net cash $6.5B. Source: 10-Q filed 2025-10-28.

Metric	REGN	Rating	Context
Debt to Equity	0.1x	Excellent	Conservative capital structure
Net Cash Position	$6.5B	Excellent	Net cash positive

---

Valuation: REGENERON PHARMACEUTICALS, INC. trades at 12.9x earnings

P/E 12.9x. EV/Sales -0.5x. FCF yield 7.1%. Source: 10-Q filed 2025-10-28.

Metric	REGN	Rating	Context
P/E Ratio	12.9x	Adequate	Reasonable valuation
EV/Sales	-0.5x	Excellent	Attractive revenue multiple
FCF Yield	7.1%	Good	Attractive cash return

---

Capital Allocation: REGENERON PHARMACEUTICALS, INC. returns 6.3% shareholder yield

Total shareholder yield 6.3% (buyback 6.3%). Capital returned $4.0B TTM. Source: 10-Q filed 2025-10-28.

Metric	REGN	Rating	Context
Total Shareholder Yield	6.3%	Excellent	Dividend + buyback yield combined
Buyback Yield	6.3%	Good	Active share repurchases
Total Capital Returned (TTM)	$4.0B	Good	Dividends + buybacks returned to shareholders

---

Sector Rankings

Metric	Value	Percentile	vs Median
Return on Invested Capital (ROIC)	14.1%	Top 25%	-
Free Cash Flow Margin	29.6%	Top 5%	-
Gross Margin	100.0%	Top 25%	1.6x above
Operating Margin	25.9%	Top 25%	9.7x above
Return on Equity (ROE)	15.4%	Top 25%	-
P/E Ratio	12.9x	N/A	-

---

Financial Scorecard

Metric	REGN	Rating	Sector Context
Return on Invested Capital (ROIC)	14.1%	Good	Top 25% of sector (median: -2.6%)
Free Cash Flow Margin	29.6%	Excellent	Top 5% of sector (median: 0.0%)
Gross Margin	100.0%	Excellent	Top 25% of sector (median: 64.3%)
Debt to Equity Ratio	6.4%	Excellent	Conservative capital structure
P/E Ratio (Price-to-Earnings)	12.9x	Adequate	Attractively valued
Free Cash Flow Yield	7.1%	Good	Solid cash yield

---

Frequently Asked Questions

Q: What is REGENERON PHARMACEUTICALS, INC.'s Return on Invested Capital (ROIC)?

REGENERON PHARMACEUTICALS, INC. (REGN) has a trailing twelve-month Return on Invested Capital (ROIC) of 14.1%. Sector median -2.6%. Source: 10-Q filed 2025-10-28.

Q: What is REGENERON PHARMACEUTICALS, INC.'s Free Cash Flow Margin?

REGENERON PHARMACEUTICALS, INC. (REGN) has a free cash flow margin of 29.6%, generating $4.2 billion in free cash flow over the trailing twelve months. Source: 10-Q filed 2025-10-28.

Q: What is REGENERON PHARMACEUTICALS, INC.'s P/E ratio and how does it compare to peers?

REGENERON PHARMACEUTICALS, INC. (REGN) trades at a P/E ratio of 12.9x, which is above the sector median of N/A. EV/Sales -0.5x. FCF yield 7.1%. Source: 10-Q filed 2025-10-28.

Q: What is REGENERON PHARMACEUTICALS, INC.'s revenue and earnings growth?

REGENERON PHARMACEUTICALS, INC. (REGN) grew revenue by 2.9% year-over-year. EPS +3.4% YoY. Source: 10-Q filed 2025-10-28.

Q: Is REGENERON PHARMACEUTICALS, INC. buying back stock?

REGENERON PHARMACEUTICALS, INC. (REGN) repurchased $3.7 billion of stock over the trailing twelve months. This represents a buyback yield of 6.3%. Source: 10-Q filed 2025-10-28.

Q: How does REGENERON PHARMACEUTICALS, INC. compare to competitors in Healthcare?

Compared to other companies in Healthcare, REGENERON PHARMACEUTICALS, INC. (REGN) shows: ROIC 14.1%, sector median -2.6% (Top 25%). FCF margin 29.6%, sector median 0.0% (Top 5%). Gross margin 100.0%, 35.7pp above sector median. These rankings are based on MetricDuck's analysis of all Healthcare companies with available SEC filings.

Q: What warning signs should I watch for with REGENERON PHARMACEUTICALS, INC.?

No quantitative warning flags fired for REGENERON PHARMACEUTICALS, INC. (REGN) on margin trend, FCF trend, ROIC trend, or leverage thresholds. Source: 10-Q filed 2025-10-28.

---

Data Source: Data sourced from 10-Q filed 2025-10-28. TTM metrics as of Q3 2025.

Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.

Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.

This analysis is for informational purposes only and does not constitute investment advice.